Tachykinins and neurokinin receptors in bone marrow functions: Neural-hematopoietic link

Journal of Receptor, Ligand and Channel Research

Volumn 3, Issue , 2010, Pages 51-61

  Klassert, Tilman E ^a,c   Patel, Shyam A ^a,b   Rameshwar, Pranela ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b University of Medicine and Dentistry of New Jersey   (United States)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Crosstalk; Hematopoiesis; Neurokinin receptor; Regulation; Tachykinins

Indexed keywords

CYCLIC AMP; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ A; SUBSTANCE P; TACHYKININ; TACHYKININ RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW; ENZYME ACTIVITY; FEEDBACK SYSTEM; HEMATOPOIESIS; HUMAN; IMMUNE SYSTEM; LYMPHOID PROGENITOR CELL; MOLECULAR INTERACTION; NEUROMODULATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW;

EID: 77952787781     PISSN: None     EISSN: 1178699X     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Patel N, Castillo M, Rameshwar P. An in vitro method to study the effects of hematopoietic regulators during immune and blood cell development. Biol Proced Online. 2007;(9):56-64.
2. Metcalf D. Hematopoietic cytokines. Blood. 2008;111(2):485-491.
3. Van Hagen PM, Krenning EP, Kwekkeboom DJ, et al. Somatostatin and the immune and haematopoetic system: a review. Eur J Clin Invest. 1994;24(2):91-99.
4. Maestroni GJM. Adrenergic regulation of haematopoiesis. Pharmacol Res. 1995;32(5):249-252.
5. Greco SJ, Corcoran KE, Cho CJ, Rameshwar P. Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Front Biosci. 2004;(9):1782-1793.
6. Rameshwar P, Poddar A, Gascón P. Hematopoietic regulation mediated by interactions among the neurokinins and cytokines. Leuk Lymphoma. 1997;28(1-2):1-10.
7. Pinto FM, Almeida TA, Hernández M, Devillier P, Advenier C, Candenas, ML. mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol. 2004;494 (2-3):233-239.
8. Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol (Lond). 1931;72(1):74-87.
9. Chang MM, Leeman SE, Niall HD. Amino acid sequence of substance P. Nature. 1971;232(29):86-87.
10. Kimura S, Okada M, Sugita Y, Kanazawa I, Munekata E. Novel Neuropeptides, Neurokinin α and β, Isolated from Porcine Spinal Cord. Proc Jpn Acad. 1983;(59):101-104.
11. Kangawa K, Minamino N, Fukuda A, Matsuo H. Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun. 1983;114(2):533-540.
12. Nawa H, Doteuchi M, Igano K, Inouye K, Nakanishi S. Substance K: a novel mammalian tachykinin that differs from substance P in its pharmacological profile. Life Sci. 1984;34(12):1153-1160.
13. Liu K, Castillo MD, Murthy RG, Patel N, Rameshwar P. Tachykinins and hematopoiesis. Clin Chim Acta. 2007;385(1-2):28-34.
14. Page NM. Hemokinins and endokinins. Cell Mol Life Sci. 2004;61(13):1652-1663.
15. Almeida TA, Rojo J, Nieto PM, Pinto FM, et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem. 2004;11(15):2045-2081.
16. MacDonald MR, McCourt DW, Krause JE. Posttranslational processing of alpha-, beta-, and gamma-preprotachykinins. Cell-free translation and early posttranslational processing events. J Biol Chem. 1988;263(29):15176-15183.
17. Eipper BA, Stoffers DA, Mains RE. The biosynthesis of neuropeptides: peptide alpha-amidation. Annu Rev Neurosci. 1992;(15):57-85.
18. Joshi DD, Dang A, Yadav P, et al. Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. Blood. 2001;98(9):2697-2706.
19. Klassert TE, Pinto F, Hernández M, et al. Differential expression of neurokinin B and hemokinin-1 in human immune cells. J Neuroimmunol. 2008;196(1-2):27-34.
20. Zhang Y, Berger A, Milne CD, Paige CJ. Tachykinins in the immune system. Curr Drug Targets. 2006;7(8):1011-1020.
21. Chavolla-Calderón M, Bayer MK, Fontán JJ. Bone mar row transplantation reveals an essential synergy between neuronal and hemopoietic cell neurokinin production in pulmonary inflammation. J Clin Invest. 2003;111(7):973-980.
22. Page NM, Bell NJ, Gardiner S, et al. Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci U S A. 2003;100(10):6245-6250.
23. Ho WZ, Douglas SD. Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol. 2004;157(1-2):48-55.
24. Nowicki M, Ostalska-Nowicka D, Kondraciuk B, Miskowiak B. The significance of substance P in physiological and malignant haematopoiesis. J Clin Pathol. 2007;60(7):749-755.
25. Sudakov SK, Medvedeva OF, Rusakova IV, Terebilina NN, Goldberg SR. Differences in genetic predisposition to high anxiety in two inbred rat strains: role of substance P, diazepam binding inhibitor fragment and neuropeptide Y. Psychopharmacol. 2001;154(4):327-335.
26. Stockmeier CA, Shi X, Konick L, et al. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport. 2002;13(9):1223-1227.
27. Rioux L, Joyce JN. Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease. J Neural Transm Park Dis Dement Sect. 1993;6(3):199-210. (Pubitemid 2022846)
28. Vink R, Nimmo AJ, Cernak I. An overview of new and novel pharmacotherapies for use in traumatic brain injury. Clin Exp Pharmacol Physiol. 2001;28(11):919-921.
29. Stumm R, Culmsee C, Schafer MK, Krieglstein J, Weihe E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J Neurosci. 2001;21(3):798-811.
30. Liu H, Sankar R, Shin DH, Mazarati AM, Wasterlain CG. Patterns of status epilepticus-induced substance P expression during development. Neuroscience. 2000;101(2):297-304.
31. Gerard NP, Bao L, Xiao-Ping H, Gerard C. Molecular aspects of the tachykinin receptors. Regul Pept. 1993;43(1-2):21-35.
32. Attwood TK. A compendium of specific motifs for diagnosing GPCR subtypes. Trends Pharmacol Sci. 2001;22(6):162-165.
33. Maggi CA. The mammalian tachykinin receptors. General Pharmacol. 1995;26(5):911-944.
34. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci. 2004;74(12):1445-1463.
35. Ramkissoon SH, Patel HJ, Taborga M, Rameshwar P. G protein-coupled receptors in haematopoietic disruption. Expert Opin Biol Ther. 2006;6(2):109-120.
36. Fong TM, Anderson SA, Yu H, Huang RRC, Strader CD. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol. 1992;41(1):24-30.
37. Lai JP, Lai S, Tuluc F, et al. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci U S A. 2008;105(34):12605-12610.
38. Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol. 2009;30(6):271-276.
39. Douglas SD, Lai JP, Tuluc F, Schwartz L, Kilpatrick LE. Neurokinin-1 receptor expression and function in human macrophages and brain: Perspective on the role in HIV neuropathogenesis. Ann NY Acad Sci. 2008;1144(1):90-96.
40. Grant AD, Akhtar R, Gerard NP, Brain SD. Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms. J Physiol. 2002;543(3):1007-1114.
41. Bandari PS, Qian J, Oh HS, et al. Crosstalk between neurokinin receptors is relevant to hematopoietic regulation: cloning and characterization of neurokinin-2 promoter. J Neuroimmunol. 2003;138(1-2):65-75.
42. Quartara L, Maggi CA.The tac hykinin NK1 receptor Part I: ligands and mechanisms of cellular activation. Neuropeptides. 1997;31(6):537-563.
43. Valant C, Maillet E, Bourguignon JJ, et al. Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration. J Med Chem. 2009;52(19):5999-6011.
44. Palanche T, Ilien B, Zoffmann S, et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem. 2001;276(37):34853-34861.
45. Williams R, Zou X, Hoyle GW. Tachykinin-1 receptor stimulates proinflammatory gene expression in lung epithelial cells through activation of NF-kappaB via a G(q)-dependent pathway. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):430-437.
46. Krause JE, Bu JY, Takeda Y, et al. Structure, expression and second messenger-mediated regulation of the human and rat substance P receptors and their genes. Regul Pept. 1993;46(1-2):59-66. (Pubitemid 23208287)
47. Janelsins BM, Mathers AR, Tkacheva OA, et al. Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood. 2009;113(13):3017-3026.
48. Corcoran KE, Rameshwar P. Nuclear factor-kappaB accounts for the repressor effects of high stromal cell-derived factor-1alpha levels on Tac1 expression in nontumorigenic breast cells. Mol Cancer Res. 2007a;5(4):373-381.
49. Jorgensen R, Holliday ND, Hansen JL, et al. Characterization of G-protein coupled receptor kinase interaction with the neurokinin-1 receptor using bioluminescence resonance energy transfer. Mol Pharmacol. 2008;73(2):349-358.
50. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002;115(Pt 3):455-465.
51. Bennett VJ, Perrine SA, Simmons MA. Neurokinin-1 receptor resensitization precedes receptor recycling. J Pharmacol Exp Ther. 2005;313(3): 1347-1354.
52. Cottrell GS, Padilla B, Pikios S, et al. Ubiquitin-dependent down-regulation of the neurokinin-1 receptor. J Biol Chem. 2006;281(38): 27773-27783.
53. Vauquelin G, Van Liefde I. G protein-coupled receptors: a count of 1001 conformations. Fundam Clin Pharmacol. 2005;19(1):45-56.
54. Hastrup H, Schwartz TW. Septide and neurokinin A are high affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis. FEBS Lett. 1996;399(3):264-266.
55. Rameshwar P, Ganea D, Gascón P. In vitro stimulatory effect of substance P on hematopoiesis. Blood. 1993;81(2):391-398.
56. Rameshwar P, Gascon P. Induction of negative hematopoietic regulators by neurokinin-A in bone marrow stroma. Blood. 1996;88(1):98-106.
57. Simmons PJ, Levesque JP, Zannettino AC. Adhesion molecules in haemopoiesis. Baillieres Clin Haematol. 1997;10(3):485-505.
58. Zon LI. Developmental biology of hematopoiesis. Blood. 1995;86(8):2876-2891.
59. Kondo M, Wagers AJ, Manz MG, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol. 2003;(21):759-806.
60. Martinez-Agosto JA, Mikkola HK, Hartenstein V, Banerjee U. The hematopoietic stem cell and its niche: a comparative view. Genes Dev. 2007;21(23):3044-3060.
61. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009;460(7252):259-263.
62. Sugimura R, Li L. Shifting in balance between osteogenesis and adipogenesis substantially influences hematopoiesis. J Mol Cell Biol. 2010;2(2):61-62.
63. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2(4):313-319.
64. Rodríguez JP, Astudillo P, Ríos S, Pino AM. Involvement of adipogenic potential of human bone mar row mesenchymal stem cells (MSCs) in osteoporosis. Curr Stem Cell Res Ther. 2008;3(3):208-218.
65. Corcoran KE, Trzaska KA, Fernandes H, et al. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One. 2008;3(6):e2563.
66. Matsuoka S, Tsuji K, Hisakawa H, et al. Generation of definitive hematopoietic stem cells from murine early yolk sac and paraaortic splanchnopleures by aorta-gonad-mesonephros region-derived stromal cells. Blood. 2001;98(1):6-12.
67. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 1993;81(11):2844-2853. (Pubitemid 23162099)
68. Müller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells. 1995;13(5):477-486.
69. Meunch MD, Schneider JG, Moore MAS. Interaction amongst colony stimulating factors, IL-1b, IL-6 and kit-ligand in the regulation of primitive murine hematopoietic cells. Exp Hematol. 1992;20(3):339-349.
70. Grebien F, Kerenyi MA, Kovacic B, et al. Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood. 2008;111(9):4511-4522.
71. North TE, de Bruijn MF, Stacy T, et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity. 2002;16(5):661-672.
72. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106(6):1901-1910.
73. Corcoran KE, Patel N, Rameshwar P. Stromal derived growth factor-1alpha: another mediator in neural-emerging immune system through Tac1 expression in bone marrow stromal cells. J Immunol. 2007;178(4):2075-2082.
74. Tabarowski Z, Gibson-Berry K, Felten SY. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochem. 1996;98(4):453-457.
75. Zhang Y, Paige CJ. T-cell developmental blockage by tachykinins antagonists and the role of hemokinin 1 in T lymphopoiesis. Blood. 2003;102(6):2165-2172.
76. Tsuda T, Wong D, Dolovich J, Bienenstock J, Marshall J, Denbury JA. Synergistic effects of nerve growth factor and granulocyte-macrophage colony-stimulating factor on human basophilic cell differentiation. Blood. 1991;77(5):971-979.
77. Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nature Immunol. 2002;3(5):477-482.
78. Bischoff SC, Dahinden CA. Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood. 1992;79(10):2662-2669.
79. Murthy RG, Greco SJ, Taborga M, Patel N, Rameshwar P. Tac1 regulation by RNA-binding protein and miRNA in bone marrow stroma: Implication for hematopoietic activity. Brain Behav Immun. 2008;22(4):442-450.
80. Corcoran KE, Malhotra A, Molina CA, Rameshwar P. Stromal-derived factor-1alpha induces a non-canonical pathway to activate the endocrine-linked Tac1 gene in non-tumorigenic breast cells. J Mol Endocrinol. 2008;40(3):113-123.
81. Singh D, Joshi DD, Hameed M, et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci U S A. 2000;97(1):388-393.
82. Kang HS, Trzaska KA, Corcoran K, Chang VT, Rameshwar P. Neurokinin receptors: relevance to the emerging immune system. Arch Immunol Ther Exp (Warsz). 2004;52(5):338-347.
83. Perez LE, Alpdogan O, Shieh JH, et al. Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp Hematol. 2004;32(3):300-307.
84. Hattori K, Heissig B, Rafii S. The regulation of hematopoietic stem cell and progenitor mobilization by chemokine SDF-1. Leuk Lymphoma. 2003;44(4):575-582.
85. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 2005;12(1):84-89.
86. Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P. RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc Natl Acad Sci U S A. 2009;106(11):4408-4413.
87. Rameshwar P, Ganea D, Gascon P. Induction of IL-3 and granulocyte-macrophage colony-stimulating factor by substance P in bone marrow cells is partially mediated through the release of IL-I and IL-6. J Immunol. 1994;152(8):4044-4054.
88. Rameshwar P, Joshi DD, Yadav P, et al. Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P-immunoreactivity in patients with bone marrow fibrosis. Blood. 2001;97(10):3025-3031.
89. Fras C, Kravetz P, Mody DR, Heggeness MH. Substance P-containing nerves within the human vertebral body: an immunohistochemical study of the basiverterbral nerve. Spine J. 2003;3(1):63-67.
90. Goto T, Tanaka T. Tachykinins and tachykinin receptors in the bone. Microsc Res Tech. 2002;(58):91-97.
91. Rameshwar P, Gascon P. Neural regulation of hematopoiesis by the tachykinins. Mol Biol Hemat. 1996;(5):463-470.
92. Zhang Y, Lu L, Furlonger C, et al. Hemokinin is a hematopoietic specific tachykinin that regulates B lymphopoiesis. Nat Immunol. 2000;1(5):392-397.
93. Rameshwar P, Gascon P, Ganea D. Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol. 1993;151(5):2484-2496.
94. Rameshwar P. Substance P: a regulatory neuropeptide for hematopoiesis and immune functions. Clin Immunol Immunopathol. 1997;85(2):129-133.
95. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988;241(4870):1218-1221.
96. Laurenzi MA, Persson MAA, Dalsgaard CJ, Haegerstrand A. The neuropeptide substance P stimulates production of interleukin I in human blood monocytes: Activated cells are preferentially influenced by the neuropeptide. Scand J Immunol. 1990;31(4):529-533.
97. Cozens PJ, Rowe FM. Substance P is a potent inducer of TNF and IL-1 secretion by macrophages. A potent role for TNF in the pathogenesis of asthma. Immunobiology. 1987;175:7-15.
98. Kimball ES, Persico FJ, Vaught JL. Substance P, neurokinin A, and neurokinin B induce generation of IL-I-like activity in P388D1 cells. Possible relevance to arthritic disease. J Immunol. 1988;141(10):3564-3569.
99. Wagner F, Fink R, Hart R, Dancygier H. Substance P enhances interferon-γ production by human peripheral blood mononuclear cells. Regul Pept. 1987;19(5-6):355-364.
100. Rameshwar P, Gascon P, Ganea D. Immunoregulatory effects of neuropeptides Stimulation of interleukin-2 production by Substance P. J Neuroimmunol. 1992;37(1-2):65-74.
101. Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-α gene expression in murine mast cells. J Immunol. 1993;150(10):4478-4485.
102. Rameshwar P, Gascon P. Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: Potential autoregulatory role for these cytokines in SP receptor expression and induction. Blood. 1995;86(2):482-490.
103. Vishalakumar S, Patel H, Moharita AL, Harrison JS, Rameshwar P. The anti-proliferative effect of neurokinin-A on hematopoietic progenitor cells is partly mediated by p53 activating the 5′ flanking region of neurokinin-2 receptor. Cell Signal. 2006;18(4):422-432.
104. Ricardo M, Trzaska KA, Rameshwar P. Neurokinin-A inhibits cell cycle activators in K562 cells and activates Smad 4 through a noncanonical pathway: a novel method in neural-hematopoietic axis. J Neuroimmunol. 2008;204(1-2):85-91.
105. Bandari PS, Qian J, Yehia G, et al. Differences in the expression of neurokinin receptor in neural and bone marrow mesenchymal cells: implications for neuronal expansion from bone marrow cells. Neuropeptides. 2001;36(1):13-21.
106. Simeonidis S, Castagliuolo I, Pan A, et al. Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-κB site on its promoter. Proc Natl Acad Sci U S A. 2003;100(5):2957-2962.
107. Vazquez-Prado J, Casas-Gonzalez P, Garcia-Sainz JA. G protein-coupled receptor cross-talk: pivotal roles of protein phosphorylation and protein- protein interactions. Cell Signal. 2003;15(6):549-557.
108. 2-adrenoreceptor and muscarinic acetylcholine receptor: implications for gene-gene interactions and bronchodilatory responses in patients with asthma and COPD. Curr Pharmacogen Pers Med. 2008;6(4):302-319.
109. Sun J, Ramnath RD, Tamizhselvi R, Bhatia M. Role of protein kinase C and phosphoinositide 3-kinase-Akt in substance P-induced proinflammatory pathways in mouse macrophages. FASEB J. 2009;23(4):997-1010.
110. Sassone-Corsi P. Transcription factors responsive to cAMP. Annu Rev Cell Dev Biol. 1995;(11):355-377.
111. Barnes PJ. Receptor heterodimerization: a new level of cross-talk. J Clin Invest. 2006;116(5):1210-1212.
112. Greco SJ, Smirnov SV, Murthy RG, Rameshwar P. Synergy between the RE-1 silencer of transcription and NFkappaB in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells. J Biol Chem. 2007;282(41):30039- 30050.
113. Rameshwar P, Gascon P, Bandari PS, Joshi DD, Fernandes A, Dang A. Structural similarity between the bone marrow extracellular matrix protein and neurokinin 1 could be the limiting factor in the hematopoietic effects of substance P. Can J Pharmacol Physiol. 2002;80(5):475-481.